| Primary |
| Epilepsy |
20.1% |
| Prophylaxis |
17.4% |
| Status Epilepticus |
14.6% |
| Convulsion |
13.5% |
| Convulsion Prophylaxis |
5.7% |
| Product Used For Unknown Indication |
5.2% |
| Anaesthesia |
3.1% |
| Sedation |
2.9% |
| Ill-defined Disorder |
2.6% |
| Fluid Replacement |
2.1% |
| Hypertension |
2.1% |
| Postoperative Care |
1.6% |
| Cerebral Infarction |
1.3% |
| Constipation |
1.3% |
| Encephalopathy |
1.3% |
| Prophylaxis Against Gastrointestinal Ulcer |
1.3% |
| Cardiac Failure |
1.0% |
| Escherichia Infection |
1.0% |
| Oedema |
1.0% |
| Brain Oedema |
0.8% |
|
| Thrombocytopenia |
12.5% |
| Toxic Epidermal Necrolysis |
12.5% |
| Respiratory Arrest |
8.8% |
| Rhabdomyolysis |
8.8% |
| Toxicity To Various Agents |
6.3% |
| Rash |
5.0% |
| Vomiting |
5.0% |
| Blood Creatine Phosphokinase Increased |
3.8% |
| Hypotension |
3.8% |
| Medication Error |
3.8% |
| Oedema Peripheral |
3.8% |
| Overdose |
3.8% |
| Respiratory Depression |
3.8% |
| Supraventricular Extrasystoles |
3.8% |
| Blood Lactate Dehydrogenase Increased |
2.5% |
| Brain Neoplasm |
2.5% |
| Cardiotoxicity |
2.5% |
| Death |
2.5% |
| Dyspnoea |
2.5% |
| Encephalitis |
2.5% |
|
| Secondary |
| Epilepsy |
15.1% |
| Fluid Replacement |
10.9% |
| Status Epilepticus |
10.7% |
| Convulsion |
9.6% |
| Prophylaxis |
8.7% |
| Oedema |
7.0% |
| Prophylaxis Against Gastrointestinal Ulcer |
3.8% |
| Analgesic Therapy |
3.5% |
| Brain Oedema |
3.5% |
| Constipation |
3.5% |
| Electrolyte Substitution Therapy |
3.5% |
| Hyperglycaemia |
3.5% |
| Nausea |
3.5% |
| Hyperammonaemia |
2.9% |
| Sedation |
2.7% |
| Drug Use For Unknown Indication |
2.1% |
| Gastrointestinal Haemorrhage |
1.4% |
| Pneumonia Aspiration |
1.4% |
| Anaesthesia |
1.3% |
| Convulsion Prophylaxis |
1.3% |
|
| Brain Neoplasm |
36.5% |
| Toxicity To Various Agents |
15.1% |
| Toxic Epidermal Necrolysis |
4.8% |
| Vomiting |
4.8% |
| Intestinal Ischaemia |
4.0% |
| Rhabdomyolysis |
3.2% |
| Status Epilepticus |
3.2% |
| Hepatic Function Abnormal |
2.4% |
| Medication Error |
2.4% |
| Muscle Spasms |
2.4% |
| Pneumonia |
2.4% |
| Post Procedural Haemorrhage |
2.4% |
| Pyrexia |
2.4% |
| Renal Impairment |
2.4% |
| Thrombocytopenia |
2.4% |
| Urinary Bladder Haemorrhage |
2.4% |
| White Blood Cell Count Decreased |
2.4% |
| Cerebral Infarction |
1.6% |
| Cytolytic Hepatitis |
1.6% |
| Drug Ineffective |
1.6% |
|
| Concomitant |
| Product Used For Unknown Indication |
38.1% |
| Epilepsy |
9.1% |
| Convulsion |
5.1% |
| Status Epilepticus |
5.1% |
| Breast Cancer Metastatic |
4.6% |
| Depression |
4.6% |
| Drug Use For Unknown Indication |
4.1% |
| Acute Lymphocytic Leukaemia |
3.0% |
| Cardio-respiratory Arrest |
3.0% |
| Liver Transplant |
3.0% |
| Acute Graft Versus Host Disease |
2.5% |
| Borderline Personality Disorder |
2.5% |
| Grand Mal Convulsion |
2.5% |
| Pain |
2.5% |
| Anxiety |
2.0% |
| Bone Pain |
2.0% |
| Anaemia |
1.5% |
| Bone Marrow Conditioning Regimen |
1.5% |
| Nausea |
1.5% |
| Premedication |
1.5% |
|
| Status Epilepticus |
18.8% |
| Urinary Tract Infection |
12.5% |
| Drug Ineffective |
6.3% |
| Hepatitis Toxic |
6.3% |
| Sepsis |
6.3% |
| Thrombotic Microangiopathy |
6.3% |
| Anaemia Haemolytic Autoimmune |
3.1% |
| Aplasia |
3.1% |
| Brain Injury |
3.1% |
| Candidiasis |
3.1% |
| Cerebrovascular Accident |
3.1% |
| Drug Interaction |
3.1% |
| Fracture |
3.1% |
| Haemorrhage Intracranial |
3.1% |
| Hepatic Failure |
3.1% |
| Infusion Related Reaction |
3.1% |
| Metabolic Acidosis |
3.1% |
| Multi-organ Failure |
3.1% |
| Nausea |
3.1% |
| Neurological Symptom |
3.1% |
|
| Interacting |
|
|
